Erioflorin Stabilizes the Tumor Suppressor Pdcd4 by Inhibiting Its Interaction with the E3-ligase β-TrCP1
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Loss of the tumor suppressor Pdcd4 was reported for various tumor entities and proposed as a prognostic marker in tumorigenesis. We previously characterized decreased Pdcd4 protein stability in response to mitogenic stimuli, which resulted from p70(S6K1)-dependent protein phosphorylation, β-TrCP1-mediated ubiquitination, and proteasomal destruction. Following high-throughput screening of natural product extract libraries using a luciferase-based reporter assay to monitor phosphorylation-dependent proteasomal degradation of the tumor suppressor Pdcd4, we succeeded in showing that a crude extract from Eriophyllum lanatum stabilized Pdcd4 from TPA-induced degradation. Erioflorin was identified as the active component and inhibited not only degradation of the Pdcd4-luciferase-based reporter but also of endogenous Pdcd4 at low micromolar concentrations. Mechanistically, erioflorin interfered with the interaction between the E3-ubiquitin ligase β-TrCP1 and Pdcd4 in cell culture and in in vitro binding assays, consequently decreasing ubiquitination and degradation of Pdcd4. Interestingly, while erioflorin stabilized additional β-TrCP-targets (such as IκBα and β-catenin), it did not prevent the degradation of targets of other E3-ubiquitin ligases such as p21 (a Skp2-target) and HIF-1α (a pVHL-target), implying selectivity for β-TrCP. Moreover, erioflorin inhibited the tumor-associated activity of known Pdcd4- and IκBα-regulated αtranscription factors, that is, AP-1 and NF-κB, altered cell cycle progression and suppressed proliferation of various cancer cell lines. Our studies succeeded in identifying erioflorin as a novel Pdcd4 stabilizer that inhibits the interaction of Pdcd4 with the E3-ubiquitin ligase β-TrCP1. Inhibition of E3-ligase/target-protein interactions may offer the possibility to target degradation of specific proteins only as compared to general proteasome inhibition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990 · cited 1×
“MLN4924 was identified to inhibit cullin-RING E3ubiquitin ligases (CRL) by attenuating the NEDD8-activating enzyme and thus, preventing neddylation of CRLs [45].”
BackgroundOhh, M., Park, C. W., Ivan, M., Hoffman, M. A., Kim, T.-Y., Huang, L. E., Pavletich, N., Chau, V., & Kaelin, W. G. (2000) · Nature Cell Biology · doi:10.1038/35017054 · Cited by 1,577 · cited 1×
“Therefore, we analyzed the effect of erioflorin on the stability of HIF-1a protein, which is targeted for proteasomal degradation by the E3-ligase von HippelLindau protein (pVHL) [41].”
BackgroundThe SCF ubiquitin ligase: insights into a molecular machine
Cardozo, T., & Pagano, M. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1471 · Cited by 1,114
Sheedy, F. J., Palsson-McDermott, E., Hennessy, E. J., Martin, C., O'Leary, J. J., Ruan, Q., Johnson, D. S., Chen, Y., & O'Neill, L. A. J. (2010) · Nature Immunology · doi:10.1038/ni.1828 · Cited by 1,005
Yang, H.-S., Jansen, A. P., Komar, A. A., Zheng, X., Merrick, W. C., Costes, S., Lockett, S. J., Sonenberg, N., & Colburn, N. H. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.1.26-37.2003 · Cited by 494 · cited 1×
“factor (eIF) 4A by displacing the scaffold protein eIF4G from its binding to the RNA helicase eIF4A [1].”
BackgroundSelf-citationEpidermal Expression of the Translation Inhibitor Programmed Cell Death 4 Suppresses Tumorigenesis
Jansen, A. P., Camalier, C. E., & Colburn, N. H. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2119 · Cited by 212
Self-citationYang, H.-S., Matthews, C. P., Clair, T., Wang, Q., Baker, A. R., Li, C.-C. H., Tan, T.-H., & Colburn, N. H. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.4.1297-1306.2006 · Cited by 202 · cited 1×
“AP-1 was chosen based on previous reports, which showed that Pdcd4 affects AP-1 activity [24,50], while NF-kB was selected since it is the direct target of the above analyzed IkBa [39].”
MethodSelf-citationMudduluru, G., Medved, F., Grobholz, R., Jost, C., Gruber, A., Leupold, J. H., Post, S., Jansen, A., Colburn, N. H., & Allgayer, H. (2007) · Cancer · doi:10.1002/cncr.22983 · Cited by 196
Self-citationYang, H.-S., Jansen, A. P., Nair, R., Shibahara, K., Verma, A. K., Cmarik, J. L., & Colburn, N. H. (2001) · Oncogene · doi:10.1038/sj.onc.1204137 · Cited by 185 · cited 2×
“1(+)-Pdcd4 plasmid [24] using the QuikChange kit (Agilent Technologies, Waldbronn, Germany) according to the manufacturer’s protocol.”
MethodSelf-citationLeupold, J. H., Yang, H.-S., Colburn, N. H., Asangani, I., Post, S., & Allgayer, H. (2007) · Oncogene · doi:10.1038/sj.onc.1210234 · Cited by 163
Self-citationPdcd4 suppresses tumor phenotype in JB6 cells by inhibiting AP-1 transactivation
Yang, H.-S., Knies, J. L., Stark, C., & Colburn, N. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206433 · Cited by 160 · cited 1×
“Pdcd4 attenuates neoplastic transformation, AP-1 transactivation, intravasation, and invasion in vitro [2,3].”
BackgroundSelf-citationTranslation Inhibitor Pdcd4 Is Targeted for Degradation during Tumor Promotion
Schmid, T., Jansen, A. P., Baker, A. R., Hegamyer, G., Hagan, J. P., & Colburn, N. H. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-1719 · Cited by 151 · cited 4×
“In line with the concept that TPA-induced degradation of Pdcd4 requires active PI3K-mTOR-p70 signaling [5,11], inhibition of p70 [35] or upstream factors such as BCR/ABL [36] was previously shown to block Pdcd4 degradation.”
BackgroundSelf-citationJansen, A. P., Camalier, C. E., Stark, C., & Colburn, N. H. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.103.3.2 · Cited by 132 · cited 1×
“Interestingly, loss of Pdcd4 appears not to be attributable to mutational inactivation [8].”
BackgroundSelf-citationInflammation-induced loss of Pdcd4 is mediated by phosphorylation-dependent degradation
Schmid, T., Bajer, M. M., Blees, J. S., Eifler, L. K., Milke, L., Rübsamen, D., Schulz, K., Weigert, A., Baker, A. R., Colburn, N. H., et al. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr131 · Cited by 39
Self-citation
Cited by
The role of ubiquitination in tumorigenesis and targeted drug discovery
Deng, L., Meng, T., Chen, L., Wei, W., & Wang, P. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0107-0 · Cited by 744
Van Roey, K., Uyar, B., Weatheritt, R. J., Dinkel, H., Seiler, M., Budd, A., Gibson, T. J., & Davey, N. E. (2014) · Chemical Reviews · doi:10.1021/cr400585q · Cited by 502
SCF ubiquitin ligase-targeted therapies
Skaar, J. R., Pagan, J. K., & Pagano, M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4432 · Cited by 335
Cuadrado, A., Cazalla, E., Bach, A., Bathish, B., Naidu, S. D., DeNicola, G. M., Dinkova-Kostova, A. T., Fernández-Ginés, R., Grochot-Przeczek, A., Hayes, J. D., et al. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103569 · Cited by 28
Grkovic, T., Blees, J., Bayer, M., Colburn, N., Thomas, C., Henrich, C., Peach, M., McMahon, J., Schmid, T., & Gustafson, K. (2014) · Marine Drugs · doi:10.3390/md12084593 · Cited by 20
Self-citation
Metadata
- Authors
- Blees, J. S., Bokesch, H. R., Rübsamen, D., Schulz, K., Milke, L., Bajer, M. M., Gustafson, K. R., Henrich, C. J., McMahon, J. B., Colburn, N. H., Schmid, T., & Brüne, B.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-10-02
- Volume
- 7
- Issue
- 10
- Pages
- e46567
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2121841892
- Cited by
- 62
- References
- 14
- FWCI
- 1.63
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.